Aceclidine Medicine 04 June 2026 Extended indication Treatment of presbyopia in adults Therapeutic value Total cost Registration phase Registration application pending Product Active substance Aceclidine Domain Neurological disorders Reason of inclusion New medicine (specialité) Main indication Eye disorders Extended indication Treatment of presbyopia in adults Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer LENZ Portfolio holder Mechanism of action Route of administration Ocular Therapeutical formulation Eye drops Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date March 2026 Expected Registration April 2027 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05753189; NCT05728944 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 1,000.00 - 1,100.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks De prijs in Nederland is nog niet bekend. In de VS is de prijs voor 25 single-use vials $81,16. De prijs per dosis bedraagt daar dan $3,25. Dit betekent ongeveer $1.200 per jaar per patiënt. Dit betekent ongeveer 1030 euro per patiënt per jaar. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks